The global antibiotics market is likely to grow at a significant CAGR in the forecast period. Antibiotics are medicinal drugs that completely eliminate the other bacteria whereas some prevent the growth. The ones that kill bacteria could be termed as bactericidal while those inhibiting the growth are inferred as bacteriostatic. Antibiotics are commonly referred to as antibacterial antibiotic compounds and differentiated as antifungals, antibacterial, and antivirals; revealing their identity as microorganisms.
Antibiotics market is significantly driven by increase in research & development by pharmaceutical companies from the developing nations. Production of generic drugs has played a significant role in development of antibiotics. Production of antibiotic drugs comprises generic medicines especially for the low-income group in the major countries. Additionally, generic industries have played a significant role in shaping the pharmaceutical industry at a regional level.
By class, the antibiotics market segmentation includes quinolones, sulfinoamides, tetracyclines, aminoglycosides, phenicols, and beta lactams. Beta lactams dominated the market scenario in the recent past. Geographical segmentation for antibiotic market includes North America, South America, Europe, Asia-Pacific, Middle East and Africa. Asia-Pacific is projected to rise at a significant CAGR in the forthcoming period owing to presence of medical institutions, manufacturing setups, and a wide availability of patient pool.
North American and European markets are likely to gain a significant growth in the forecast period owing to rise in mortality due to pneumonia, tuberculosis, and moderate availability of antibiotics. The rise in number of contagious diseases is likely to drive the demand for antibiotics. MEA market is likely to gain a significant share in the forecast period owing to rise in prevalence of contagious disease and demand for medical drugs.
The key players in the antibiotics industry include Pfizer, Inc., Abbott Laboratories, GlaxoSmithKline PLC, Daiichii Sankyo Company Limited, Bayer HealthCare Pharmaceuticals LLC, Astellas Pharma, Inc., Merck & Company Inc., Roche Holding AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., GlaxoSmithKline Plc, Pliva, Toyama Chemical Co. Ltd. and Takeda Pharmaceutical Company. Ltd., Johnson & Johnson, LG Life Sciences Limited, and Eli Lilly.
Global Antibiotics Drug Class Outlook (Revenue, USD Million, 2013 - 2024)
Global Mechanism Outlook (Revenue, USD Million, 2013 - 2024)
• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
Antibiotics Regional Outlook (Revenue, USD Million, 2013 - 2024)
• North America
• Asia Pacific
• Latin America
• South Africa
Research Support Specialist, USA